Today it would be fair to allocate the responsibilities of a possible unwanted pregnancy not only on her shoulders , but also on him. Soon it may enter into the trade pillolo , similar to a male contraceptive pill for women.
The pill is composed of two hormones : a progestin and an estrogen , the pillolo from a progestogen and testosterone .
Today we are at a good point of ” experimentation phase ” (which has been running for 7 years) and will be on the market in 2018.
The contraceptive efficacy of pillolo begins after they have spent about 12 weeks from start of treatment (3 months) . So blocking the production of sperm does not happen instantly , so this may not have a contraceptive occasional use , the pillolo also offers no protection against sexually transmitted diseases . To the casual relationships or risk condom use remains absolutely essential.
The compound is called JQ1 and its action is to penetrate the blood into the tissue of the testis , going to disrupt spermatogenesis , the process by which they develop mature sperm , which could , in fact, fertilize the woman . During ejaculation there will still be the issue of ” semen “, but this will not make active sperm .
The process is reversible : the production of sperm resumes as soon as you stop treatment with JQ1 .
The positives are that you are having health problems in offspring conceived after discontinuation of therapy and no decrease in sexual desire .
So far it has been very difficult to find a solution to male fertility drug given the higher level of challenge than the female counterpart : while the woman produces one egg a month, men produce millions of sperm every day .
The concerns of some specialists are currently not from a medical standpoint , but from a psychological one : given that the erection mechanism is a very delicate, perhaps , the power of consciousness do not produce sperm may also be influenced by the physical point of view the “patient ” .
We will then see how the trial will proceed . At the moment all the volunteers of the experiment were fully satisfied.
If you are interested in participating in the trial is to undergo an informational interview at the Department of Obstetrics and Gynecology , University of Bologna, Via Massarenti 13 (Bo) . Please book by calling Monday to Friday from 9.00 am to 17.00 at 051-6363716 ( the person in charge is Dr. Maria Cristina Meriggiola ) .